Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
21 Décembre 2023 - 1:00PM
Business Wire
The programme aims to design a potential best
in class molecule by combining Exscientia's research platform with
Sanofi's leading development expertise
Exscientia eligible for additional upfront and
research stage milestones on top of existing agreement
Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is
adding a new discovery stage programme identified and initially
advanced by Exscientia into the current collaboration. In this
programme, Exscientia has designed a novel lead series with a
potential best in class profile, with preliminary data showing good
potency and selectivity towards the target and differentiated
molecular properties.
“Sanofi adding an Exscientia discovery stage programme into the
collaboration speaks to the strengths of our AI-driven platform to
solve complex drug discovery problems,” said Professor Andrew
Hopkins FRS FMedSci, founder and Chief Executive Officer of
Exscientia. “The growth of our collaboration is a testament to our
strong relationship with Sanofi and our shared vision for
AI-enabled drug discovery. As we enter 2024, we expect to continue
working with partners to apply our platform capabilities across
therapeutic areas while maintaining our internal pipeline focus on
high value oncology targets.”
Under the terms of the amended agreement, Exscientia is eligible
for up to $45 million in upfront and preclinical milestone
payments. Exscientia will also be eligible for additional
development, regulatory and sales-based milestone payments of over
$300 million and tiered royalties on product sales ranging from
high-single-digits to mid-teens, as described in the original
collaboration agreement. The upfront payment is expected to be
reflected in the first quarter 2024 results for Exscientia as cash
inflows from collaborations and recognised as revenue over the
duration of the agreement.
About Exscientia Exscientia is an AI-driven
precision medicine company committed to discovering, designing and
developing the best possible drugs in the fastest and most
effective manner. Exscientia developed the first-ever functional
precision oncology platform to successfully guide treatment
selection and improve patient outcomes in a prospective
interventional clinical study, as well as to progress AI-designed
small molecules into the clinical setting. Our internal pipeline is
focused on leveraging our precision medicine platform in oncology,
while our partnered pipeline broadens our approach to other
therapeutic areas. By pioneering a new approach to medicine
creation, we believe the best ideas of science can rapidly become
the best medicines for patients.
Visit us on www.exscientia.ai or follow us on Twitter
@exscientiaAI.
Forward-Looking Statements This press release
contains forward-looking statements as that term is defined in the
Private Securities Litigation Reform Act of 1995, including with
respect to the progress of discovery and development of candidate
molecules. Any statement describing Exscientia’s goals, plans,
expectations, projections, intentions or beliefs is a
forward-looking statement and should be considered an at-risk
statement. Such statements are subject to a number of risks,
uncertainties and assumptions, including those related to the
process of discovering, developing and commercialising product
candidates that are safe and effective for use as human
therapeutics; and the endeavour of building a business around such
product candidates. In light of these risks and uncertainties, and
other risks and uncertainties that are described in the Risk
Factors section and other sections of Exscientia’s Annual Report on
Form 20-F, filed with the Securities and Exchange Commission (SEC)
on March 23, 2022 (File No. 001-40850), and other filings that
Exscientia makes with the SEC from time to time (which are
available at https://www.sec.gov/), the events and circumstances
discussed in such forward-looking statements may not occur, and
Exscientia’s actual results could differ materially and adversely
from those anticipated or implied thereby. Although Exscientia’s
forward-looking statements reflect the good faith judgement of its
management, these statements are based only on facts and factors
currently known by the Company. As a result, you are cautioned not
to rely on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231221360521/en/
Investor Relations: Sara Sherman
investors@exscientia.ai
Media: Oliver Stohlmann media@exscientia.ai
Exscientia (NASDAQ:EXAI)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Exscientia (NASDAQ:EXAI)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024